GI Dynamics
Teleflex announces plans to cut costs and streamline manufacturing | Medtech Wall Street news for the week of May 5, 2014
Weight loss: GI Dynamics raises $32M with private placement
GI Dynamics (ASX:GID) said it raised about $31.7 million (A$34.3 million) in a private placement with a group of "sophisticated, professional and accredited investors" overseas.
Weight loss: GI Dynamics notches milestones in Israel, Netherlands
Weight-loss devices maker GI Dynamics (ASX:GID) announced a couple of new wins in recent weeks, tallying new reimbursement coverage from healthcare officials in Israel and the Netherlands.
GI Dynamics lands German reimbursement win
GI Dynamics (ASX:GID) said it won a reimbursement nod in Germany for its flagship EndoBarrier weight loss and diabetes device.
Reimbursement process begins in Switzerland, Germany for GI Dynamics’ EndoBarrier
GI Dynamics (ASX:GID) said Swiss and German regulators took the 1st steps toward reimbursement in those countries for its EndoBarrier weight loss and diabetes device.
Diabetes: GI Dynamics pulls in $35M tranche in $52M round
GI Dynamics (ASX:GID) said it’s pulled in nearly $35 million as part of a $52 million funding round it’s planning to use to back a U.S. trial of its EndoBarrier device.
The Lexington, Mass.-based medical device company said in a regulatory filing that it’s drummed up $34.8 million from 13 unnamed investors.
Weight loss: GI Dynamics raises $52M, announces share purchase plan
GI Dynamics (ASX:GID) said it’s raised roughly $52.2 million (A$57.5 million) in a private placement and is offering another $2.3 million (A$2.5 million) in a stock purchase plan for existing shareholders.
Weight loss: France bankrolls EndoBarrier cost trial for GI Dynamics
French regulators will fund a trial looking at the cost and utility of the EndoBarrier device for Type II diabetes and weight loss made by GI Dynamics (ASX:GID).
Weight loss: GI Dynamics adds centers in Europe
GI Dynamics (ASX:GID) said another 5 medical centers in Europe are online with its EndoBarrier weight loss and diabetes device.
The Lexington, Mass.-based medical device company said centers in Spain, Switzerland and 3 in Germany are now implanting the device, a gut liner designed to inhibit the uptake of nutrients from food.
Weight loss: GI Dynamics’ U.S. clinical trial taxes its coffers
Investors Down Under shied away from weight-loss devices maker GI Dynamics (ASX:GID) today after president & CEO Stuart Randle told shareholders that the company may need to raise new funds in order to support its clinical trials.